Form 8-K
8-K — NEUROONE MEDICAL TECHNOLOGIES Corp
Accession: 0001213900-26-043239
Filed: 2026-04-14
Period: 2026-04-14
CIK: 0001500198
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item: Financial Statements and Exhibits
Documents
8-K — ea0286106-8k_neuroone.htm (Primary)
EX-3.1 — CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION (ea028610601ex3-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0286106-8k_neuroone.htm · Sequence: 1
false
--09-30
0001500198
0001500198
2026-04-14
2026-04-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April
14, 2026
NeuroOne Medical Technologies Corporation
(Exact name of registrant as specified in its charter)
Delaware
001-40439
27-0863354
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
7599 Anagram Dr., Eden Prairie, MN 55344
(Address of principal executive offices and zip code)
952-426-1383
(Registrant’s telephone number including area code)
(Registrant’s former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
NMTC
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year.
On April 14, 2026, NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”) filed an amendment
to its Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock
split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).
As previously disclosed, at its annual meeting of stockholders held on April 3, 2026, and upon the recommendation of the Company’s
Board of Directors (the “Board”), the Company’s stockholders approved a certificate of amendment to effect a reverse
stock split of the Common Stock at a ratio ranging from any whole number between 1-for-2 and 1-for-15, as determined by the Board in its
discretion (the “Certificate of Amendment”).
On April 3, 2026, the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-6. The Company has filed the Certificate
of Amendment to effect a 1-for-6 reverse stock split of its shares of Common Stock, to be effective as of 5:00 p.m. Eastern Time on April
15, 2026 (the “Reverse Stock Split”).
As a result of the Reverse Stock
Split, every 6 shares of the Company’s Common Stock issued or outstanding will be automatically reclassified into one validly issued,
fully-paid and non-assessable new share of Common Stock, subject to the treatment of fractional shares as described below, without any
action on the part of the holders. Proportional adjustments will be made to the number of shares of Common Stock awarded and available
for issuance under the Company’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the
exercise or conversion of the Company’s outstanding stock options and other equity securities under the Company’s equity incentive
plans. All outstanding warrants will also be adjusted in accordance with their terms. The shares of Common Stock outstanding following
the Reverse Stock Split will remain fully paid and non-assessable. The Reverse Stock Split will not affect the number of authorized shares
of Common Stock or the par value of the Common Stock.
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive
fractional shares as a result of the Reverse Stock Split will automatically be entitled to receive a cash payment equal to the market
value of the fractional share. The Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s
relative interest in the Company’s equity securities, except for any adjustments for fractional shares.
Trading of the Common Stock on
The Nasdaq Capital Market will commence on a split-adjusted basis at market open on April 16, 2026, under the existing trading symbol
“NMTC.” The new CUSIP number for the Company’s Common Stock following the Reverse Stock Split will be 64130M308.
The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference
to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Form 8-K and is incorporated herein
by reference.
1
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form
8-K includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information
contained in this Form 8-K may be a forward looking statement that reflects NeuroOne’s current views about future events and
are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking
statements. In some cases, you can identify forward looking statements by the words or phrases “may,”
“might,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “forecasts,” “objective,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,”
“target,” “seek,” “contemplate,” “continue, “focused on,” “committed
to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements
about the future. Forward looking statements may include statements regarding the reverse stock split and the timing thereof, the
impact of the reverse stock split, including any adjustments that may result from the treatment of fractional shares, and option and
warrant holders, the potential impact of the reverse stock split on the bid price of the Company’s common stock, the potential
for the Company to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements
are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from what we expect due to factors largely outside our control,
including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements,
risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology whether due to
supply chain disruptions, labor shortages or otherwise risks that our technology will not perform as expected based on results of
our pre-clinical and clinical trials risks related to uncertainties associated with the Company’s capital requirements to
achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage
or adequate reimbursement for our technology uncertainties inherent in the development process of our technology risks related to
changes in regulatory requirements or decisions of regulatory authorities that we may not have accurately estimated the size and
growth potential of the markets for our technology risks related to clinical trial patient enrollment and the results of clinical
trials that we may be unable to protect our intellectual property rights and other risks, uncertainties and assumptions, including
those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These
forward looking statements speak only as of the date of this Form 8-K and NeuroOne undertakes no obligation to revise or update any
forward looking statements for any reason, even if new information becomes available in the future.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No.
Description
3.1
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation.
104
Cover Page Interactive Data File (Embedded within the Inline XBRL Document).
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: April 14, 2026
By:
/s/ David Rosa
David Rosa
Chief Executive Officer
3
EX-3.1 — CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUROONE MEDICAL TECHNOLOGIES CORPORATION
EX-3.1
Filename: ea028610601ex3-1.htm · Sequence: 2
Exhibit 3.1
CERTIFICATE OF
AMENDMENT TO THE
CERTIFICATE OF INCORPORATION OF
NEUROONE MEDICAL TECHNOLOGIES CORPORATION
NEUROONE MEDICAL TECHNOLOGIES
CORPORATION (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation
Law of the State of Delaware (the “DGCL”), does hereby certify that:
FIRST: The name of the Corporation
is NeuroOne Medical Technologies Corporation and the date on which the Certificate of Incorporation of the Corporation was originally
filed with the Secretary of State of the State of Delaware was June 26, 2017 (the “Certificate of Incorporation”);
SECOND: The Board of Directors
of the Corporation has duly adopted resolutions proposing and declaring advisable that the Certificate of Incorporation be amended as
set forth herein and calling for the consideration and approval thereof at a meeting of the stockholders of the Corporation;
THIRD: The Certificate of Incorporation
is hereby amended by deleting the Paragraph A of ARTICLE IV in its entirety and inserting the following in lieu thereof:
“The Corporation is authorized
to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock”.
The total number of shares that the Corporation is authorized to issue is One Hundred Ten Million (110,000,000) shares, each with a par
value of $0.001 per share. One Hundred Million (100,000,000) shares shall be Common Stock and Ten Million (10,000,000) shares shall be
Preferred Stock. Upon the filing and effectiveness (the “Effective Time”) pursuant to the General Corporation
Law of the State of Delaware (the “DGCL”) of this Certificate of Amendment to the Certificate of Incorporation
of the Corporation, as previously amended (the “Restated Certificate”), each six (6) shares of the Corporation’s
Common Stock issued and outstanding immediately prior to the Effective Time shall, automatically and without any action on the part of
the Corporation or respective holders thereof, be combined and converted into one (1) validly issued, fully paid and non-assessable share
of Common Stock (the “Reverse Split”); provided, however, that the Corporation shall issue no fractional shares
as a result of the actions set forth herein but shall instead pay to the holder of such fractional share a sum in cash equal to such fraction
multiplied by the closing sales price of the Common Stock as reported on The Nasdaq Capital Market on the last trading day before the
Effective Time (as adjusted to give effect to the Reverse Split).”
FOURTH: Pursuant to a resolution
of Board of Directors of the Corporation, this Certificate of Amendment was submitted to the stockholders of the Company for their approval,
and was duly adopted in accordance with the provisions of Section 242 of the DGCL.
FIFTH: This Certificate of Amendment
to the Certificate of Incorporation shall have an Effective Time of April 15, 2026 at 5:00 p.m. Eastern Time.
IN WITNESS WHEREOF, NeuroOne Medical
Technologies Corporation has caused this Certificate of Amendment to be executed by its duly authorized officer on this 14th
day of April, 2026.
NEUROONE MEDICAL TECHNOLOGIES CORPORATION
By:
/s/ David Rosa
Name:
David Rosa
Title:
Chief Executive Officer
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.1
Cover
Apr. 14, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Apr. 14, 2026
Current Fiscal Year End Date
--09-30
Entity File Number
001-40439
Entity Registrant Name
NeuroOne Medical Technologies Corporation
Entity Central Index Key
0001500198
Entity Tax Identification Number
27-0863354
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
7599 Anagram Dr.
Entity Address, City or Town
Eden Prairie
Entity Address, State or Province
MN
Entity Address, Postal Zip Code
55344
City Area Code
952
Local Phone Number
426-1383
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.001 per share
Trading Symbol
NMTC
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details
Name:
dei_CurrentFiscalYearEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:gMonthDayItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration